Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease

Translational Psychiatry

Volumn 7, Issue 6, 2017, Pages

  Janel, N ^a   Alexopoulos, P ^b,c   Badel, A ^a   Lamari, F ^d   Camproux, A C ^a   Lagarde, J ^a   Simon, S ^e   Feraudet Tarisse, C ^e   Lamourette, P ^e   Arbones, M ^f   Paul, J L ^g   Dubois, B ^h   Potier, M C ⁱ   Sarazin, M ^a   Delabar, J M ⁱ  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF PATRAS   (Greece)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e DIF   (France)

^f INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; DYRK KINASE; HOMOCYSTEINE; MONOCLONAL ANTIBODY; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

AGED; ALZHEIMER DISEASE; ANIMAL; BLOOD; C57BL MOUSE; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; TRANSGENIC MOUSE;

AGED; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; ROC CURVE;

EID: 85032344084     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2017.123     Document Type: Article

References (52)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's dis-ease. Lancet 2011; 377: 1019–1031.
2. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011; 69: 203–213.
3. Souchet B, Guedj F, Sahun I, Duchon A, Daubigney F, Badel A et al. Excitation/ inhibition balance and learning are modified by Dyrk1a gene dosage. Neurobiol Dis 2014; 69: 65–75.
4. Hamelet J, Noll C, Ripoll C, Paul JL, Janel N, Delabar JM. Effect of hyperhomo-cysteinemia on the protein kinase DYRK1A in liver of mice. Biochem Biophys Res Commun 2009; 378: 673–677.
5. Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K et al. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife 2015; 4: 05920.
6. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007; 16: 15–23.
7. Guedj F, Sebrie C, Rivals I, Ledru A, Paly E, Bizot JC et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 2009; 4: e4606.
8. Toiber D, Azkona G, Ben-Ari S, Toran N, Soreq H, Dierssen M. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol Dis 2010; 40: 348–359.
9. Noll C, Planque C, Ripoll C, Guedj F, Diez A, Ducros V et al. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS ONE 2009; 4: e7540.
10. Planque C, Dairou J, Noll C, Bui LC, Ripoll C, Guedj F et al. Mice deficient in cystathionine beta synthase display increased Dyrk1A and SAHH activities in brain. J Mol Neurosci 2013; 50: 1–6.
11. Abekhoukh S, Planque C, Ripoll C, Urbaniak P, Paul JL, Delabar JM et al. Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in the brain of hyperhomocysteinemic mice. Mol Neurobiol 2013; 47: 105–116.
12. Janel N, Sarazin M, Corlier F, Corne H, de Souza LC, Hamelin L et al. Plasma DYRK1A as a novel risk factor for Alzheimer's disease. Transl Psychiatry 2014; 4: e425.
13. Tlili A, Hoischen A, Ripoll C, Benabou E, Badel A, Ronan A et al. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients. Mol Neurobiol 2012; 46: 297–303.
14. Platenik J, Fisar Z, Buchal R, Jirak R, Kitzlerova E, Zverova M et al. GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depres-sion. Prog Neuropsychopharmacol Biol Psychiatry 2014; 50: 83–93.
15. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 2011; 7: 412–417.
16. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280–292.
17. Grimmer T, Wutz C, Drzezga A, Forster S, Forstl H, Ortner M et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res 2013; 10: 82–85.
18. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270–279.
19. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263–269.
20. Lazar AN, Bich C, Panchal M, Desbenoit N, Petit VW, Touboul D et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol over-load in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol 2013; 125: 133–144.
21. Guedj F, Pereira PL, Najas S, Barallobre MJ, Chabert C, Souchet B et al. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol Dis 2012; 46: 190–203.
22. Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol 2002; 22: 6636–6647.
23. Bui LC, Tabouy L, Busi F, Dupret JM, Janel N, Planque C et al. A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase. Anal Biochem 2014; 449: 172–178.
24. Reik LM, Maines SL, Ryan DE, Levin W, Bandiera S, Thomas PE. A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. J Immunol Methods 1987; 100: 123–130.
25. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid col-orimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95.
26. Grassi J, Frobert Y, Pradelles P, Chercuitte F, Gruaz D, Dayer JM et al. Production of monoclonal antibodies against interleukin-1 alpha and-1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J Immunol Methods 1989; 123: 193–210.
27. Volland H, Vulliez Le Normand B, Mamas S, Grassi J, Creminon C, Ezan E et al. Enzyme immunometric assay for leukotriene C4. J Immunol Methods 1994; 175: 97–105.
28. Ducros V, Demuth K, Sauvant MP, Quillard M, Causse E, Candito M et al. Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 781: 207–226.
29. Neto E, Biessmann F, Aurlien H, Nordby H, Eichele T. Regularized linear dis-criminant analysis of EEG features in dementia patients. Front Aging Neurosci 2016; 8: 273.
30. Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr 2016; 36: 211–239.
31. Ori-McKenney KM, McKenney RJ, Huang HH, Li T, Meltzer S, Jan LY et al. Phos-phorylation of beta-tubulin by the Down syndrome kinase, minibrain/DYRK1a, regulates microtubule dynamics and dendrite morphogenesis. Neuron 2016; 90: 551–563.
32. Ruiz-Mejias M, Martinez de Lagran M, Mattia M, Castano-Prat P, Perez-Mendez L, Ciria-Suarez L et al. Overexpression of Dyrk1A, a Down syndrome candidate, decreases excitability and impairs gamma oscillations in the prefrontal cortex. J Neurosci 2016; 36: 3648–3659.
33. Lee Y, Ha J, Kim HJ, Kim YS, Chang EJ, Song WJ et al. Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis. J Biol Chem 2009; 284: 33343–33351.
34. Jin N, Yin X, Gu J, Zhang X, Shi J, Qian W et al. Truncation and activation of dual specificity tyrosine phosphorylation-regulated kinase 1A by Calpain I: a molecular mechanism linked to tau pathology in Alzheimer disease. J Biol Chem 2015; 290: 15219–15237.
35. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238–249.
36. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64: 238–258.
37. Carrard A, Salzmann A, Perroud N, Gafner J, Malafosse A, Karege F. Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism. Brain Behav 2011; 1: 119–124.
38. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T et al. Associations of serum brain-derived neurotrophic factor with cognitive impair-ments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1836–1840.
39. Koenigsberg HW, Yuan P, Diaz GA, Guerreri S, Dorantes C, Mayson S et al. Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients. Psychiatry Res 2012; 199: 92–97.
40. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695–702.
41. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 1999; 58: 729–739.
42. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 2008; 89: 312–323.
43. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromol Med 2011; 13: 217–222.
44. Komulainen P, Pedersen M, Hanninen T, Bruunsgaard H, Lakka TA, Kivipelto M et al. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 596–603.
45. Forlenza OV, Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonca VA et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 2010; 11: 774–780.
46. Rabaneda LG, Geribaldi-Doldan N, Murillo-Carretero M, Carrasco M, Martinez-Salas JM, Verastegui C et al. Altered regulation of the Spry2/Dyrk1A/PP2A triad by homocysteine impairs neural progenitor cell proliferation. Biochim Biophys Acta 2016; 1863: 3015–3026.
47. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl JMed2002; 346: 476–483.
48. Zylberstein DE, Lissner L, Bjorkelund C, Mehlig K, Thelle DS, Gustafson D et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 2011; 32: 380–386.
49. Hamelet J, Couty JP, Crain AM, Noll C, Postic C, Paul JL et al. Calpain activation is required for homocysteine-mediated hepatic degradation of inhibitor I kappa B alpha. Mol Genet Metab 2009; 97: 114–120.
50. Jang Y, Kim J, Ko JW, Kwon YH. Homocysteine induces PUMA-mediated mito-chondrial apoptosis in SH-SY5Y cells. Amino Acids 2016; 48: 2559–2569.
51. Zhang Y, Liao JM, Zeng SX, Lu H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep 2011; 12: 811–817.
52. Lu M, Zheng L, Han B, Wang L, Wang P, Liu H et al. REST regulates DYRK1A transcription in a negative feedback loop. J Biol Chem 2011; 286: 10755–10763.